Experimental autoimmune encephalomyelitis

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE) is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). It is mostly used with rodents and is widely studied as an animal model of the human CNS demyelinating diseases, including multiple sclerosis and acute disseminated encephalomyelitis (ADEM). EAE is also the prototype for T-cell-mediated autoimmune disease in general.

EAE was motivated by observations during the convalescence from viral diseases by Thomas M. Rivers, D. H. Sprunt and G. P. Berry in 1933. Their findings upon a transfer of inflamed patient tissue to primates was published in the Journal of Experimental Medicine.[1][2] An acute monophasic illness, it has been suggested that EAE is far more similar to ADEM than MS.[3]

EAE can be induced in a number of species, including mice, rats, guinea pigs, rabbits and primates. The most commonly used antigens in rodents are spinal cord homogenate (SCH), purified myelin, myelin protein such as MBP, PLP and MOG, or peptides of these proteins, all resulting in distinct models with different disease characteristics regarding both immunology and pathology.[4][5] It may also be induced by the passive transfer of T cells specifically reactive to these myelin antigens.[6] Depending on the antigen used and the genetic make-up of the animal, rodents can display a monophasic bout of EAE, a relapsing-remitting form, or chronic EAE . The typical susceptible rodent will debut with clinical symptoms around two weeks after immunization and present with a relapsing-remitting disease. The archetypical first clinical symptom is weakness of tail tonus that progresses to paralysis of the tail, followed by a progression up the body to affect the hind limbs and finally the forelimbs. However, similar to MS, the disease symptoms reflect the anatomical location of the inflammatory lesions, and may also include emotional lability, sensory loss, optic neuritis, difficulties with coordination and balance (ataxia), and muscle weakness and spasms. Recovery from symptoms can be complete or partial and the time varies with symptoms and disease severity. Depending on the relapse-remission intervals, rats can have up to 3 bouts of disease within an experimental period.

EAE in mice[edit]

Demyelination is produced by injection of brain extracts, CNS proteins (such as myelin basic protein), or peptides from such protein emulsified in an adjuvant such as complete Freund's adjuvant. The presence of the adjuvant allows the generation of inflammatory responses to the protein/peptides. In many protocols, mice are coinjected with pertussis toxin to break down the blood-brain barrier and allow immune cells access to the CNS tissue. This immunisation leads to multiple small disseminated lesions of demyelination (as well as micro-necroses) in the brain and spinal cord and the onset of clinical symptoms.

Although sharing some features, mostly demyelination, this model, first introduced in 1930s, differs from human MS in several ways. EAE either kills animals or leaves them with permanent disabilities; animals with EAE also suffer severe nerve inflammation, and the time course of EAE is entirely different from MS, being the main antigen (MBP) in charge.

Secondary damage in EAE[edit]

Given that some conditions as MS show cortical damage together with the WM damage, there has been interest if this can appear as a secondary damage of the WM. It seems that some researchers claim so.[7]

EAE in humans[edit]

Sometimes the human equivalent to EAE has been triggered in humans by accident or medical mistake. The reactions have been diverse according to the sources of the disease[8][9] The researchers in this report have termed the condition "Human autoimmune encephalitis" (HAE).

The damage in the second report fulfilled all pathological diagnostic criteria of MS and can therefore be classified as MS in its own right. The lesions were classified as pattern II in the Lucchinetti system. This case of human EAE also showed Dawson fingers[9]

Using the confluent demyelination as barrier between MS and ADEM,[10] some other reports about EAE in humans classify its effects as ADEM but not always. In Japanese patients exposed to rabies vaccine that contained neural tissue, the clinical presentation resembled ADEM more than MS but the lesions were like acute multiple sclerosis (Uchimura and Shiraki, 1957).[11]

New forms of EAE[edit]

Since the discovery of the four lucchinetti patterns, new EAE models have been published, specifically mimicking the patterns I and II. DTH-EAE for pattern I (T cell and macrophage-mediated delayed-type hypersensitivity) and fMOG-EAE for pattern II (antibody-mediated focal myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalitis)[12]

Alternatives[edit]

Recently it has been found that CSF from MS patients can carry the disease to rodents, opening the door to an alternative model.[13]

Notes and references[edit]

  1. ^ Rivers TM, Spunt DH, Berry GP (1933). "OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS". Journal of Experimental Medicine 58: 39–53. doi:10.1084/jem.58.1.39. 
  2. ^ Rivers TM, Schwentker FF (1935). "Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys". Journal of Experimental Medicine 61: 689–701. doi:10.1084/jem.61.5.689. PMC 2133246. PMID 19870385. 
  3. ^ Sriram S, Steiner I (2005). "Experimental Allergic Encephalomyelitis: A misleading model of Multiple Sclerosis". Annals of Neurology 58: 939–945. doi:10.1002/ana.20743. PMID 16315280. 
  4. ^ MANNIE, M., R. H. SWANBORG and J. A. STEPANIAK, 2009 Experimental autoimmune encephalomyelitis in the rat. Curr Protoc Immunol Chapter 15: Unit 15 12
  5. ^ MILLER, S. D., and W. J. KARPUS, 2007 Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol Chapter 15: Unit 15 11
  6. ^ Ellwardt, Erik; Zipp, Frauke (2014). "Molecular mechanisms linking neuroinflammation and neurodegeneration in MS". Experimental Neurology 262: 8–17. doi:10.1016/j.expneurol.2014.02.006. 
  7. ^ Zipp Frauke, Ellwardt Erik, Pramanik Guatam, Mittmann Thomas, Stroh Albrecht (2016). "Cortical Hyperactivity beyond the Immune Attack: Starting Point of Neurodegeneration". Neurology 86 (16 Supplement): S2.002. 
  8. ^ Lassman Hans (Feb 2010). "Acute disseminated encephalomyelitis and multiple sclerosis". Brain 133: 317–319. doi:10.1093/brain/awp342. PMID 20129937. 
  9. ^ a b Höftberger R, Leisser M, Bauer J, Lassmann H (Dec 2015). "Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis?". Acta Neuropathol Commun 3 (1): 80. doi:10.1186/s40478-015-0260-9. PMC 4670499. PMID 26637427. 
  10. ^ Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, Thomsen KM, Mandrekar JN, Erickson BJ, Lucchinetti CF (2010). "Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis". Brain 133: 333–348. doi:10.1093/brain/awp321. 
  11. ^ Lassmann H (2010). "Acute disseminated encephalomyelitis and multiple sclerosis". Brain 133: 317–9. doi:10.1093/brain/awp342. PMID 20129937. 
  12. ^ D. Anthony et al. Anti-CD20 Therapy Down-Regulates Lesion Formation And Microglial Activation In Pattern I And Pattern II Rat Models Of Multiple Sclerosis, Neurology, April 2014 [1]
  13. ^ Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA (2014). "Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice". Exp Neurol 261: 620–32. doi:10.1016/j.expneurol.2014.07.020. PMID 25111532. 

External links[edit]